BTIG Research restated their buy rating on shares of Quotient Limited (NASDAQ:QTNT) in a research report sent to investors on Thursday morning, MarketBeat Ratings reports. The firm currently has a $12.00 price objective on the stock.

QTNT has been the subject of several other reports. Zacks Investment Research raised shares of Quotient Limited from a sell rating to a hold rating in a report on Wednesday, August 9th. ValuEngine raised shares of Quotient Limited from a strong sell rating to a sell rating in a report on Friday, June 30th.

Shares of Quotient Limited (QTNT) opened at 3.73 on Thursday. The stock’s 50 day moving average is $4.82 and its 200 day moving average is $6.37. Quotient Limited has a 52 week low of $3.22 and a 52 week high of $8.64. The firm’s market cap is $53.62 million.

Quotient Limited (NASDAQ:QTNT) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.55). Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. The business had revenue of $6.83 million during the quarter, compared to analyst estimates of $5.70 million. On average, equities research analysts predict that Quotient Limited will post ($2.09) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/04/quotient-limited-qtnt-stock-rating-reaffirmed-by-btig-research.html.

In other Quotient Limited news, insider D J. Paul E. Cowan sold 45,032 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $6.57, for a total transaction of $295,860.24. Following the completion of the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $175,195.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider D J. Paul E. Cowan sold 45,540 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $3.52, for a total transaction of $160,300.80. Following the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at $93,864.32. The disclosure for this sale can be found here. Insiders have sold a total of 265,612 shares of company stock valued at $1,443,079 over the last three months. 29.00% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund acquired a new position in Quotient Limited during the 2nd quarter valued at about $101,000. Goldman Sachs Group Inc. acquired a new position in Quotient Limited during the 2nd quarter valued at about $104,000. Nationwide Fund Advisors acquired a new position in Quotient Limited during the 2nd quarter valued at about $111,000. Birchview Capital LP boosted its stake in Quotient Limited by 36.9% during the 2nd quarter. Birchview Capital LP now owns 79,700 shares of the company’s stock valued at $587,000 after purchasing an additional 21,500 shares during the period. Finally, Nicholas Hoffman & Company LLC. acquired a new position in Quotient Limited during the 1st quarter valued at about $150,000. 57.68% of the stock is owned by hedge funds and other institutional investors.

About Quotient Limited

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Receive News & Stock Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related stocks with our FREE daily email newsletter.